Fig. 1
From: PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim
PRKCQ is sufficient to promote resistance to chemotherapy. Overexpression of kinase-active PRKCQ enhances cell viability in the presence of doxorubicin (a) or paclitaxel (b). Percent viability relative to vehicle control was determined using alamarBlue™. Kinase-active PRKCQ overexpression decreases apoptosis in response to doxorubicin or paclitaxel as determined by Caspase Glo® 3/7 Assay (c, d) and levels of cleaved PARP (CPARP) (e, f). Western blots are representative of at least 3 independent experiments. LE, light exposure; DE, dark exposure. All significance was determined using Student’s t test except b. Here, significance was calculated using Welch’s t test. PRKCQA148E: kinase active PRKCQ; PRKCQK409R: catalytically inactive PRKCQ